Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference

Bicara Therapeutics (NASDAQ: BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, FICERA, during a presentation and fireside chat at TD Cowen's 46th annual health care conference. Ryan Cohlhepp, the company's President and COO, said the company is advancing FICERA-an EGFR and TGF-beta bifunctional-into a pivotal study in frontline HPV-negative recurrent/metastatic head